CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Nxera Pharma Sets 2026 Operating Profit Forecast at Upper End of Prior Range, JPY 15.7 Billion

By Public Technologies
  • Nxera Pharma set forecasts for the year ending Dec. 31, 2026, at previous ranges' upper limits, with sales of JPY 48.8 billion.
  • Core operating profit is forecast at JPY 22.8 billion; operating profit is projected at JPY 15.7 billion.
  • The revision reflects a USD 100 million upfront payment under an exclusive global licensing agreement with AbbVie for its EP4 agonist program.
  • Expected fourth-quarter revenue includes JPY 15.78 billion from the payment, using an exchange rate of JPY 157.8 per US dollar.
  • The outlook assumes completion by year-end, subject to antitrust clearance, with revenue recognition dependent on agreement with auditors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.